Re-treatment with 177Lu-PSMA-617 for prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests if a second round of a targeted radiation therapy (177Lu-PSMA-617) can help men whose prostate cancer has returned after a successful first treatment. It is for men whose cancer has stopped responding to hormone therapy and chemotherapy, and whose PSA levels have risen again after a prior good response to this drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic castration-resistant prostate cancer (cancer that has spread and is growing despite low testosterone levels).
- You have had at least one course of chemotherapy for this cancer.
- You have taken at least one hormone-targeting pill (like enzalutamide or abiraterone).
- You completed at least 4 cycles of 177Lu-PSMA-617 before and had a good response (PSA dropped by at least half).
- After that first treatment, your PSA went up again (confirmed by two tests at least 3 weeks apart).
- You have a recent PSMA PET/CT scan showing the cancer still has the target (PSMA) and your blood counts and kidney function are adequate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two treatments for advanced prostate cancer that has stopped responding to hormone therapy. One treatment is a targeted radiation therapy (177Lu-PSMA-617) and the other is an immunotherapy (sipuleucel-T) that helps your immune system fight the cancer.
This trial is testing if a higher first dose of Lu-177-PSMA-617, a targeted radiation therapy, can improve outcomes for men with metastatic castration-resistant prostate cancer that shows up on a PSMA PET scan. The goal is to see if it is safe and effective.
This trial tests a higher dose of a radioactive drug (177Lu-PSMA-617) for men whose prostate cancer has spread and does not produce much of a protein called PSMA on scans. The goal is to see if a stronger dose can work better than the standard dose.
This trial tests two different dosing schedules of a drug called Lutetium-177 PSMA RLT, which delivers radiation directly to prostate cancer cells. It is for men with advanced prostate cancer that has stopped responding to hormone therapy and has spread, who have not yet had chemotherapy for this stage of the disease.
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
This trial tests two drugs: vorinostat (a pill that may make cancer cells easier to target) and 177Lu-PSMA-617 (a radioactive drug that seeks out prostate cancer cells). It is for men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy and shows low levels of PSMA on a PET scan.
Hear when a new Castration-Resistant Prostate Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.